Dan Schell articles
-
Making Sense Of New Accounting And Financial Reporting Changes
5/31/2019
A summary of some key sections of version 10 of Deloitte’s Life Sciences Accounting And Financial Reporting Update—Including Interpretive Guidance.
-
The Impact Of A Biotech CEO On Company Growth
5/1/2019
An inside look at how CEO Yuval Cohen communicates and interacts with employees at Corbus Pharmaceuticals, and how all of that affects the company’s culture.
-
The Rollercoaster Ride Of A Biotech CEO
4/1/2019
Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.
-
Others Talk About Creating Good Stories; We Write Them
9/28/2018
Good storytelling is the crux of every article in Life Science leader, and our October issue is no exception. Here are a few examples of what not to miss in our next issue.
-
The Appeal Of A Good Underdog Story
8/22/2018
Like many people, I’ve always loved a good underdog story, and recently Life Science Leader has had some good ones. We also have a great CEO Corner coming up in our September issue that talks about what it’s like going from being a VC to founding and running a biopharma.
-
A Positive Outcome From Pharma Closures
3/8/2017
The large changes impacting biopharma in the Delaware Valley (i.e., Philadelphia metropolitan area) have presented a rather unique opportunity for capturing surplus biomedical research assets. As many of us know all too well, facility closures and downsizing initiatives usually result in the disposal of significant quantities of expensive chemicals, starting materials, equipment, consumables, and general and specialized industrial-grade glassware. That usually meant the safe disposal of the chemicals and the remainder of the materials being sent to landfill after appropriate washing and crushing.
-
The Uphill Battle Of A Biotech That Switched Its Focus
3/8/2017
When Roger Crystal, M.D., says that he understands the importance of being “flexible” in the business of biotech, he’s not spouting typical ambiguous CEO-speak. In his case, he’s referring to his company’s willingness to pivot, to “pause” a path that they had invested years of time and resources to and choose a new core objective.
-
Biosimilars Event Chairperson Not What I Expected
5/24/2016
Although I’ve rarely traveled to shows since we launched Life Science Leader in 2009, I’m not unfamiliar with fulfilling this duty as an editor; I did it for six years prior to focusing exclusively on LSL. Still, there was one element of World Biosimilar Congress that seemed foreign to me — the role of the chairperson Richard DiCicco.
-
An Entrepreneurial Approach To Funding Drug Development
5/1/2016
The tech world is filled with stories of companies that grew from modest beginnings with minimal capital: Steve Wozniak and Steve Jobs tinkering in Jobs’ garage; Michael Dell scraping together $1,000 to buy parts and build personal computers in his dorm room at the University of Texas.
-
Advice From A Serial Pharmaceutical Entrepreneur
5/4/2015
Twenty-two years after graduating college, Michael Jaharis purchased his first pharmaceutical company. That was in 1972. Four decades later he had amassed a career — and a fortune — in the pharmaceutical industry highlighted by the sales of three companies: Key Pharmaceuticals, Kos Pharmaceuticals, and Pearl Therapeutics.